Introduction
Cerebrolysin and Semax are two of the most studied neuropeptide compounds in cognitive and neuroprotective research. Both have clinical approval histories in Eastern Europe and Russia, distinguishing them from most research peptides that lack human clinical data. While they share overlapping research applications in neuroprotection and cognitive enhancement, their compositions, mechanisms, and evidence bases differ substantially.
What Is Cerebrolysin?
Cerebrolysin is not a single synthetic peptide but a mixture of low-molecular-weight peptides and free amino acids derived from pig brain tissue through enzymatic digestion. It contains multiple neuropeptide fragments including compounds with BDNF-like, CNTF-like, NGF-like, and IGF-1-like activity. It is an approved pharmaceutical drug in multiple European and Asian countries for stroke rehabilitation, traumatic brain injury, Alzheimer’s disease, and vascular dementia.
What Is Semax?
Semax (MEHFPGP) is a fully synthetic seven-amino acid peptide analogue of the ACTH(4-10) fragment. Unlike Cerebrolysin’s complex biological mixture, Semax is a precisely defined synthetic compound with a known sequence and molecular weight. It is approved in Russia and Ukraine for cognitive dysfunction, stroke, optic nerve disease, and other neurological indications.
Mechanisms Compared
Cerebrolysin’s mechanisms are multiple and incompletely characterized, reflecting its complex mixture composition. Its effects are attributed to neurotrophic activity mimicking BDNF, NGF, and other growth factors, combined with neuroprotective and anti-apoptotic signaling. Semax works primarily through upregulation of BDNF and NGF expression, modulation of dopaminergic and serotonergic systems, and neuroprotective effects in ischemia models. Both ultimately converge on BDNF signaling as a key mechanism, but through different routes.
Clinical Evidence Comparison
Cerebrolysin has a more extensive clinical evidence base in specific neurological conditions, particularly stroke rehabilitation and Alzheimer’s disease, supported by multiple randomized controlled trials. Semax’s clinical data is primarily from Russian and Ukrainian trials, which are less accessible in Western literature. Both have regulatory approvals but in different jurisdictions and for somewhat different indications.
Research Applications
Cerebrolysin is most appropriate for research requiring a multi-factor neurotrophic intervention mimicking endogenous neurotrophic support. Semax is more appropriate for research targeting a specific, defined molecular tool for BDNF upregulation or ACTH-fragment pharmacology. For researchers requiring a reproducible, chemically defined compound, Semax is preferable. For research modeling complex neurotrophic support, Cerebrolysin’s mixture may better approximate biological complexity.
Practical Handling Differences
Cerebrolysin is supplied as an injectable solution (not reconstituted from powder) and has specific storage requirements. Semax is available as a lyophilized powder for reconstitution or as a nasal spray formulation. The synthetic nature of Semax makes it more practically compatible with standard peptide research workflows.
Conclusion
Cerebrolysin and Semax share a focus on neuroprotection and cognitive enhancement but differ fundamentally in composition, mechanism specificity, and research context. Semax offers precision as a defined synthetic compound while Cerebrolysin provides a clinically validated multi-factor neurotrophic intervention. Selection depends on whether the research requires a defined molecular tool or a complex neurotrophic mixture.